57 completed, 11 terminated, 9 recruiting, 6 unknown. 94 Phase 2, 30 Phase 1, 1 Phase 3.
Follow plerixafor: new trials by email Literature Review of plerixafor trials Research Report on plerixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Mozobil for Autologous Hematopoietic Stem Cell Transplantation Plerixafor, Gcsf - Multiple Myeloma, Hodgkin Lymphoma | Phase 2 | Recruiting | Thomas Jefferson University | 100 | 2025-10-16 | 2025-11-28 |
| Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy Plerixafor, Filgrastim, Palifermin - X-linked Severe Combined Immunodeficiency, X-SCID | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2025-05-09 | 2026-10-13 |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML Rabbit Anti thymocyte globulin, Busulfan, Fludarabine - AML, Childhood, Aml | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 68 | 2024-11-15 | 2026-08-24 |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma Elranatamab, Lenalidomide, Plerixafor - Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-17 | 2026-08-10 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells - Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2024-04-17 | 2026-08-13 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor Plerixafor - Sickle Cell Disease | Phase 2 | Withdrawn | St. Jude Children's Research Hospital | 2023-04-01 | 2023-04-07 | |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-10-16 |
| Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb) Plerixafor 20 MG/ML [Mozobil], Placebo - COVID-19 Acute Respiratory Distress Syndrome, COVID-19 | Phase 2 | Withdrawn | 4Living Biotech | 2022-07-19 | 2023-04-10 | |
| Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease MGTA-145, Plerixafor - Sickle Cell Disease | Phase 2 | Terminated | Ensoma | 1 | 2022-06-24 | 2025-07-25 |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies MGTA-145, Plerixafor - Related Donors Donating PBSC to a Family Member, Healthy Donors | Phase 2 | Terminated | Ensoma | 7 | 2021-06-16 | 2024-11-06 |
| Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer Cemiplimab, Plerixafor - Metastatic Pancreatic Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2020-11-16 | 2024-02-23 |
| MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma MGTA-145, Plerixafor - Multiple Myeloma | Phase 2 | Completed | Surbhi Sidana, MD | 25 | 2020-10-05 | 2022-09-10 |
| Reduced Intensity Transplantation for Severe Sickle Cell Disease hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus - Sickle Cell Disease | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 46 | 2020-04-30 | 2026-09-01 |
| AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma AMD3100, Pembrolizumab - Head and Neck Cancer | Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-09-30 | 2020-09-07 | |
| Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients Plerixafor, Gcsf - Chronic Granulomatous Disease | Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 17 | 2019-04-13 | 2019-09-17 |
Showing 20 of 94. Sign in to see all of them.
Multiple Myeloma (25) · Lymphoma, Non-Hodgkin (22) · Leukemia, Myeloid, Acute (17) · Hodgkin Disease (12) · Myelodysplastic Syndromes (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Anemia, Sickle Cell (7) · Lymphoma (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Fanconi Anemia (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Neoplasms, Plasma Cell (4) · Agammaglobulinemia (3) · Glioblastoma (3) · Gliosarcoma (3)
Genzyme, a Sanofi Company (14) · Washington University School of Medicine (9) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · M.D. Anderson Cancer Center (4) · Fred Hutchinson Cancer Center (3) · National Cancer Institute (NCI) (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · St. Jude Children's Research Hospital (3) · Assistance Publique - Hôpitaux de Paris (2) · Dana-Farber Cancer Institute (2) · Emory University (2) · Ensoma (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · 4Living Biotech (1) · CancerCare Manitoba (1)
United States (64) · France (5) · Canada (4) · Germany (4) · Spain (4) · Italy (3) · Belgium (2) · Israel (2) · Japan (2) · Mexico (2) · Russia (2) · United Kingdom (2) · Bulgaria (1) · China (1) · Czechia (1)
Suk S De Ravin, M.D. (3) · Akshay Sharma, MBBS (2) · David H McDermott, M.D. (2) · Lawrence Recht (2) · Leona Holmberg (2) · Mitchell Horwitz, MD (2) · Richard W Childs, M.D. (2) · Alan K Burnett (1) · Alexei Maschan, Professor (1) · Amanda F. Cashen, M.D. (1) · Arnon Nagler, MD (1) · Brandon M. Triplett, MD (1) · Camille Abboud, M.D. (1)
PMID 20067838, PMID 28292947, PMID 19135941, PMID 19167685, PMID 19483760, PMID 19597422, PMID 19720922, PMID 19929463, PMID 20530974, PMID 21890643, PMID 22308295, PMID 24244025, PMID 24523241, PMID 24723677, PMID 25105369, PMID 27118452, PMID 27535663, PMID 28067870, PMID 28797783, PMID 29392425, PMID 29472357, PMID 29550630, PMID 30043330, PMID 30890544, PMID 31456261, PMID 31501599, PMID 31618456, PMID 32127657, PMID 34175041, PMID 34485595, PMID 34515338, PMID 34538132, PMID 34751952, PMID 36163427, PMID 37561579, PMID 38691679, PMID 39348419, PMID 39384609, PMID 39413163, PMID 39624016, PMID 39642902, PMID 40330596, PMID 42606118
2014 (2), P30CA015704 (2), 2015 (1), P01CA247886 (1), P30CA033572 (1), P30CA124435 (1), P50CA107399 (1), R01HL081499 (1), U10CA180821 (1)